PARP inhibitors

[Haematologica] Scientists investigated the oncogenic function of TAL1 and the possible cooperation with PI3K-AKT pathway activation using isogenic pro-T cell cultures ex vivo and in vivo leukemia models.

[Communications Biology] Researchers reported that autophagy affected differently the response of prostate cancer cell lines to olaparib depending on its activation status.

[Clinics and Research in Hepatology and Gastroenterology] Scientists developed 2 quantifications methods to explore BRCA1 and RAD51C promoter methylation in a series of 121 Formalin Fixed-Paraffin-Embedded specimens from resected pancreatic adenocarcinoma without neoadjuvant treatment.

[Molecular Cancer therapeutics] Investigators characterized responses to olaparib in sensitive LNCaP and C4-2B cells and developed two olaparib resistant derivative cell line models from each. In LNCaP and C4-2B cells, they found that olaparib induced massive DNA damage, leading to activation of the G2/M checkpoint, activation of p53, and cell cycle arrest.

[Expert Opinion On Biological Therapy] The authors present completed and ongoing research projects regarding prostate cancer immunotherapy. Ipilimumab and olaparib were proved to prolong overall survival significantly against placebo, but a lot of research is going on to identify which patients and at what stage of disease will benefit the most before incorporating them in clinical practice.

[npj Breast Cancer] The authors characterized a population of stem-like breast cancer cells expressing the integrin αvβ3 as transcriptionally related to activated stem/basal cells in the normal human mammary gland.